Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan
- Written by ACN Newswire - Press Releases
DAYVIGO is a dual orexin receptor antagonist that inhibits orexin
Read more //?#
.
Baby boomers are driving development feasibility leading to larger apartments
As residential developers continue to grapple with feasibility issues on apartment projects, the sector is struggling to deliver volumes of new st...
Hays launches FY25/26 Salary Guide: ‘Salary Paradox’ deepens as pay rises fail Australians
Rising dissatisfaction with pay, progression and perks is fuelling a new wave of career change in FY25/26, as Australians demand more from employe...
Australian Businesses Still Stuck in the AI Hype Cycle
Data Governance Failures, ROI Gaps and Unclear Strategy Slowing Progress Despite artificial intelligence (AI) dominating headlines and boardroom ag...
How to ensure your manufacturing business survives international tariff turmoil
Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...
Why Apptio is Enhancing Visibility into AI and Hybrid Cloud
AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...
Beyond borders: Building a scalable strategy for international hiring
For many Australian businesses, growth increasingly depends on thinking beyond local borders. As wage pressures rise, and specialised talent pool...
